PDCD1 and cholangiocarcinoma: conducted a retrospective analysis of 42 advanced intrahepatic CCA patients treated with PD-1 inhibitors and reported a median OS, PFS, and time to progression (TTP) of 19.3, 11.6, and 11.6 months, respectively (18).